Boston biotech Rezera delays $200 million IPO
Rezera, a Boston biotech developing drugs to target inflammatory and cardiovascular diseases, delayed its initial public offering scheduled for Friday, a company spokesperson confirmed. The firm, previously known as NodThera, was seeking $200 million in …